NEW YORK (GenomeWeb News) – Amoy Diagnostics today said that it has reached an agreement with OxOnc Development to use Amoy's ROS1 Gene Fusions Detection Kits for a pivotal clinical trial of Pfizer's Xalkori (crizotinib).

Xiamen, China-based Amoy said that it would provide the kits to the labs conducting the study in China, Korea, and Japan. It also will provide technical support for the assay, which uses real-time PCR to detect 14 different fusion products in cDNA derived from tumor tissue or body fluids.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.